Log in

NASDAQ:MESO - Mesoblast Stock Price, Forecast & News

$9.34
0.00 (0.00 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$9.22
Now: $9.34
$9.46
50-Day Range
$7.35
MA: $9.19
$10.63
52-Week Range
$4.17
Now: $9.34
$10.88
Volume28,592 shs
Average Volume91,469 shs
Market Capitalization$931.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.74
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MESO
Previous SymbolOTCMKTS:MBLTY
CUSIPN/A
CIKN/A
Phone61-3-9639-6036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.72 million
Book Value$4.82 per share

Profitability

Net Income$-89,800,000.00
Net Margins-342.39%

Miscellaneous

Employees81
Market Cap$931.48 million
Next Earnings DateN/A
OptionableOptionable

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.


Mesoblast (NASDAQ:MESO) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How were Mesoblast's earnings last quarter?

Mesoblast limited (NASDAQ:MESO) released its quarterly earnings results on Monday, November, 25th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.09. The business earned $17.05 million during the quarter, compared to the consensus estimate of $16.48 million. Mesoblast had a negative return on equity of 15.30% and a negative net margin of 342.39%. View Mesoblast's Earnings History.

What price target have analysts set for MESO?

6 equities research analysts have issued 12-month price objectives for Mesoblast's stock. Their forecasts range from $6.00 to $23.00. On average, they anticipate Mesoblast's share price to reach $13.83 in the next year. This suggests a possible upside of 48.1% from the stock's current price. View Analyst Price Targets for Mesoblast.

What is the consensus analysts' recommendation for Mesoblast?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesoblast.

Has Mesoblast been receiving favorable news coverage?

News coverage about MESO stock has trended neutral recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mesoblast earned a news sentiment score of 0.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near future. View News Stories for Mesoblast.

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 71)

When did Mesoblast IPO?

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of of institutional and retail investors. Top institutional investors include M&G Investment Management Ltd. (1.50%), Penbrook Management LLC (0.23%), Princeton Capital Management LLC (0.11%), Renaissance Technologies LLC (0.07%), Tobias Financial Advisors Inc. (0.03%) and Wilbanks Smith & Thomas Asset Management LLC (0.03%).

Which major investors are selling Mesoblast stock?

MESO stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Renaissance Technologies LLC and Princeton Capital Management LLC.

Which major investors are buying Mesoblast stock?

MESO stock was bought by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Tobias Financial Advisors Inc., Penbrook Management LLC and Wilbanks Smith & Thomas Asset Management LLC.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $9.34.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $931.48 million and generates $16.72 million in revenue each year. The company earns $-89,800,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Mesoblast employs 81 workers across the globe.View Additional Information About Mesoblast.

What is Mesoblast's official website?

The official website for Mesoblast is http://www.mesoblast.com/.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]


MarketBeat Community Rating for Mesoblast (NASDAQ MESO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  357 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MESO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MESO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: What are no-load funds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel